Metraipolis › archive › dc_2a0035ecf81d
The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo — Europe PMC PMID:34748617
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34748617
- DOI
- 10.1371/journal.ppat.1010042
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-01T13:59:49.764Z
- SHA-256 of the archived text
9b1c5da9d1ea131be3bf22719fd384745a567a873472df222c33780122a2035c- Stable URL of this page
https://metraipolis.com/documento/dc_2a0035ecf81d
How to cite
The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo — Europe PMC PMID:34748617 — Europe PMC (en), https://europepmc.org/article/MED/34748617 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2a0035ecf81d (Metraipolis archive dc_2a0035ecf81d, sha256 9b1c5da9d1ea131be3bf22719fd384745a567a873472df222c33780122a2035c)
BibTeX
@misc{dc2a0035ecf81d,
title = {The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo — Europe PMC PMID:34748617},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34748617},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2a0035ecf81d; sha256 9b1c5da9d1ea131be3bf22719fd384745a567a873472df222c33780122a2035c},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34748617. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP junctional tetrapeptide NPDP or NVDP minor repeats while cross-reacting with NANP central repeats in vitro. The extent to which each of these epitopes is required for protection in vivo is unknown. Here, we assessed whether junction-, minor repeat- and central repeat-preferring human mAbs (CIS43, L9 and 317 respectively) bound and protected against in vivo challenge with transgenic P. berghei (Pb) SPZ expressing either PfCSP with the junction and minor repeats knocked out (KO), or PbCSP with the junction and minor repeats knocked in (KI). In vivo protection studies showed that the junction and minor repeats are necessary and sufficient for CIS43 and L9 to neutralize KO and KI SPZ, respectively. In contrast, 317 required major repeats for in vivo protection. These data establish that human mAbs can prevent malaria infection by targeting three different protective epitopes (NPDP, NVDP, NANP) in the PfCSP repeat region. This report will inform vaccine development and the use of mAbs to passively prevent malaria. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2021 (prima pubblicazione 2021-11-08). Identificativi: PMID 34748617 · PMCID PMC8601602 · DOI 10.1371/journal.ppat.1010042. Pagina: https://europepmc.org/article/MED/34748617 — https://doi.org/10.1371/journal.ppat.1010042. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-01T13:51:23.953Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.